253 related articles for article (PubMed ID: 23056280)
1. A potent class of GPR40 full agonists engages the enteroinsular axis to promote glucose control in rodents.
Luo J; Swaminath G; Brown SP; Zhang J; Guo Q; Chen M; Nguyen K; Tran T; Miao L; Dransfield PJ; Vimolratana M; Houze JB; Wong S; Toteva M; Shan B; Li F; Zhuang R; Lin DC
PLoS One; 2012; 7(10):e46300. PubMed ID: 23056280
[TBL] [Abstract][Full Text] [Related]
2. Potentiation of insulin secretion and improvement of glucose intolerance by combining a novel G protein-coupled receptor 40 agonist DS-1558 with glucagon-like peptide-1 receptor agonists.
Nakashima R; Yano T; Ogawa J; Tanaka N; Toda N; Yoshida M; Takano R; Inoue M; Honda T; Kume S; Matsumoto K
Eur J Pharmacol; 2014 Aug; 737():194-201. PubMed ID: 24858371
[TBL] [Abstract][Full Text] [Related]
3. Selective small-molecule agonists of G protein-coupled receptor 40 promote glucose-dependent insulin secretion and reduce blood glucose in mice.
Tan CP; Feng Y; Zhou YP; Eiermann GJ; Petrov A; Zhou C; Lin S; Salituro G; Meinke P; Mosley R; Akiyama TE; Einstein M; Kumar S; Berger JP; Mills SG; Thornberry NA; Yang L; Howard AD
Diabetes; 2008 Aug; 57(8):2211-9. PubMed ID: 18477808
[TBL] [Abstract][Full Text] [Related]
4. SCO-267, a GPR40 Full Agonist, Improves Glycemic and Body Weight Control in Rat Models of Diabetes and Obesity.
Ueno H; Ito R; Abe SI; Ookawara M; Miyashita H; Ogino H; Miyamoto Y; Yoshihara T; Kobayashi A; Tsujihata Y; Takeuchi K; Watanabe M; Yamada Y; Maekawa T; Nishigaki N; Moritoh Y
J Pharmacol Exp Ther; 2019 Aug; 370(2):172-181. PubMed ID: 31182471
[TBL] [Abstract][Full Text] [Related]
5. GPR40 full agonism exerts feeding suppression and weight loss through afferent vagal nerve.
Ueno H; Ito R; Abe SI; Ogino H; Maruyama M; Miyashita H; Miyamoto Y; Moritoh Y; Tsujihata Y; Takeuchi K; Nishigaki N
PLoS One; 2019; 14(9):e0222653. PubMed ID: 31525244
[TBL] [Abstract][Full Text] [Related]
6. Lack of GPR40/FFAR1 does not induce diabetes even under insulin resistance condition.
Matsuda-Nagasumi K; Takami-Esaki R; Iwachidow K; Yasuhara Y; Tanaka H; Ogi K; Nakata M; Yano T; Hinuma S; Taketomi S; Odaka H; Kaisho Y
Diabetes Obes Metab; 2013 Jun; 15(6):538-45. PubMed ID: 23331570
[TBL] [Abstract][Full Text] [Related]
7. Activation of FFA1 mediates GLP-1 secretion in mice. Evidence for allosterism at FFA1.
Xiong Y; Swaminath G; Cao Q; Yang L; Guo Q; Salomonis H; Lu J; Houze JB; Dransfield PJ; Wang Y; Liu JJ; Wong S; Schwandner R; Steger F; Baribault H; Liu L; Coberly S; Miao L; Zhang J; Lin DC; Schwarz M
Mol Cell Endocrinol; 2013 Apr; 369(1-2):119-29. PubMed ID: 23403053
[TBL] [Abstract][Full Text] [Related]
8. GPR40 partial agonist MK-2305 lower fasting glucose in the Goto Kakizaki rat via suppression of endogenous glucose production.
Miller C; Pachanski MJ; Kirkland ME; Kosinski DT; Mane J; Bunzel M; Cao J; Souza S; Thomas-Fowlkes B; Di Salvo J; Weinglass AB; Li X; Myers RW; Knagge K; Carrington PE; Hagmann WK; Trujillo ME
PLoS One; 2017; 12(5):e0176182. PubMed ID: 28542610
[TBL] [Abstract][Full Text] [Related]
9. Chronic treatment with novel GPR40 agonists improve whole-body glucose metabolism based on the glucose-dependent insulin secretion.
Tanaka H; Yoshida S; Oshima H; Minoura H; Negoro K; Yamazaki T; Sakuda S; Iwasaki F; Matsui T; Shibasaki M
J Pharmacol Exp Ther; 2013 Sep; 346(3):443-52. PubMed ID: 23853170
[TBL] [Abstract][Full Text] [Related]
10. TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats.
Tsujihata Y; Ito R; Suzuki M; Harada A; Negoro N; Yasuma T; Momose Y; Takeuchi K
J Pharmacol Exp Ther; 2011 Oct; 339(1):228-37. PubMed ID: 21752941
[TBL] [Abstract][Full Text] [Related]
11. AMG 837: a novel GPR40/FFA1 agonist that enhances insulin secretion and lowers glucose levels in rodents.
Lin DC; Zhang J; Zhuang R; Li F; Nguyen K; Chen M; Tran T; Lopez E; Lu JY; Li XN; Tang L; Tonn GR; Swaminath G; Reagan JD; Chen JL; Tian H; Lin YJ; Houze JB; Luo J
PLoS One; 2011; 6(11):e27270. PubMed ID: 22087278
[TBL] [Abstract][Full Text] [Related]
12. Discovery of Potent and Orally Bioavailable GPR40 Full Agonists Bearing Thiophen-2-ylpropanoic Acid Scaffold.
Li H; Huang Q; Chen C; Xu B; Wang HY; Long YQ
J Med Chem; 2017 Apr; 60(7):2697-2717. PubMed ID: 28277660
[TBL] [Abstract][Full Text] [Related]
13. GPR40-Mediated G
Rives ML; Rady B; Swanson N; Zhao S; Qi J; Arnoult E; Bakaj I; Mancini A; Breton B; Lee SP; Player MR; Pocai A
Mol Pharmacol; 2018 Jun; 93(6):581-591. PubMed ID: 29572336
[TBL] [Abstract][Full Text] [Related]
14. Chronic Exposure to SCO-267, an Allosteric GPR40 Full Agonist, Is Effective in Improving Glycemic Control in Rats.
Koyama R; Ookawara M; Watanabe M; Moritoh Y
Mol Pharmacol; 2021 Apr; 99(4):286-293. PubMed ID: 33547250
[TBL] [Abstract][Full Text] [Related]
15. The fatty acid receptor GPR40 plays a role in insulin secretion in vivo after high-fat feeding.
Kebede M; Alquier T; Latour MG; Semache M; Tremblay C; Poitout V
Diabetes; 2008 Sep; 57(9):2432-7. PubMed ID: 18559658
[TBL] [Abstract][Full Text] [Related]
16. β-Arrestin Recruitment and Biased Agonism at Free Fatty Acid Receptor 1.
Mancini AD; Bertrand G; Vivot K; Carpentier É; Tremblay C; Ghislain J; Bouvier M; Poitout V
J Biol Chem; 2015 Aug; 290(34):21131-21140. PubMed ID: 26157145
[TBL] [Abstract][Full Text] [Related]
17. GPR40 partial agonists and AgoPAMs: Differentiating effects on glucose and hormonal secretions in the rodent.
Pachanski MJ; Kirkland ME; Kosinski DT; Mane J; Cheewatrakoolpong B; Xue J; Szeto D; Forrest G; Miller C; Bunzel M; Plummer CW; Chobanian HR; Miller MW; Souza S; Thomas-Fowlkes BS; Ogawa AM; Weinglass AB; Di Salvo J; Li X; Feng Y; Tatosian DA; Howard AD; Colletti SL; Trujillo ME
PLoS One; 2017; 12(10):e0186033. PubMed ID: 29053717
[TBL] [Abstract][Full Text] [Related]
18. Modulating GPR40: therapeutic promise and potential in diabetes.
Poitout V; Lin DC
Drug Discov Today; 2013 Dec; 18(23-24):1301-8. PubMed ID: 24051395
[TBL] [Abstract][Full Text] [Related]
19. Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion.
Edfalk S; Steneberg P; Edlund H
Diabetes; 2008 Sep; 57(9):2280-7. PubMed ID: 18519800
[TBL] [Abstract][Full Text] [Related]
20. G protein-coupled receptor (GPR)40-dependent potentiation of insulin secretion in mouse islets is mediated by protein kinase D1.
Ferdaoussi M; Bergeron V; Zarrouki B; Kolic J; Cantley J; Fielitz J; Olson EN; Prentki M; Biden T; MacDonald PE; Poitout V
Diabetologia; 2012 Oct; 55(10):2682-2692. PubMed ID: 22820510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]